GenIP PLC - Trading Statement

25 July 2025 

GenIP Plc

("GenIP" or the "Company")

H1 2025 Trading Statement

Growing Order Book and Cash Balance

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to issue the following trading statement for H1 2025.

GenIP continues to build momentum. The Company's cash balance increased to $1,077k at 30 June 2025 (31 December 2024: $972k) driven by record orders and effective cost controls. In the first half of 2025, we secured $488k in new orders, including material contract wins in Asia, expanding our catchment market, which have positively impacted working capital.

Total orders received since GenIP's AIM listing in October 2024 stand at $981k, and the outstanding order book totals $813k, providing visibility of revenue generation in H2 2025.

The business was acquired by GenIP in June 2024 and the strategic ramp-up of expenditure and marketing took place following the October 2024 IPO, so there is no direct comparability between H1 2025 and FY2024 revenue performance.

Nevertheless, H1 2025 revenue is expected to reach approximately $128k, modestly ahead of PE2024's total ($123k). This uplift reflects the timing of several significant orders secured in the first half, which are scheduled for delivery and revenue recognition in H2. These early wins underscore the commercial progress made since IPO and position the Company for continued growth in the second half of the year.

The Company continues to maintain a strong pipeline of new business as it delivers on its global growth strategy. During the period, GenIP has entered new markets including Brazil, Chile and the UK academic market. In addition to the continued growth of existing products, the Company looks forward to enhancing revenue generation by launching new products currently in development phases. GenIP's Invention Evaluator services accounted for the majority of first half revenue and orders, with Vortechs expected to make a more significant contribution in the second half.

Investment in technology development continues with delivery expected at the beginning of Q3, serving as a growth enabler.

Outlook

GenIP is in a robust position with clear revenue visibility going into the second half of 2025. Given the typical time lag between order receipt and revenue recognition, we expect an uplift in revenue in H2 2025.  Demand for GenIP's Generative AI analytics services is strong, and the Company is laser-focused on growing its order book while continuing to maintain a robust balance sheet.

Melissa Cruz, CEO of GenIP, commented:

"We are extremely encouraged by the strong commercial traction we've achieved in such a short period since our IPO. The size and quality of our order book reflect the value our services bring to clients worldwide. We're seeing increasing demand for our solutions as institutions seek faster, data-driven ways to unlock the value of their innovations. With a strong balance sheet and a growing pipeline of opportunities, we are well positioned to deliver accelerated growth in the second half of the year and beyond."

For further information regarding GenIP, please visit www.genip.ai, or contact:

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

GenIP provides two complementary services:

1.   Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

2.   Vortechs: which is an executive recruitment service that uses  advanced machine learning algorithms and natural language processing technologies to assist in matching technology organisations with experienced executives skilled in technology commercialisation.

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

●    Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

●    Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

●    Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-